
--- Page 3 ---
Dear shareholders,
Dear shareholders, 
March 2024
March 2024 
2023 was a defining moment in Johnson & Johnson’s 
2023 was a defining moment in Johnson & Johnson's 
138-year history.
138-year history. 
It was a year of transformation and growth that has 
It was a year of transformation and growth that has 
positioned our company to be a leader in global healthcare 
positioned our company to be a leader in global healthcare 
for decades to come.
for decades to come. 
With the successful separation of our consumer health 
With the successful separation of our consumer health 
business, we entered a new era – one exclusively focused 
business, we entered a new era —  one exclusively focused 
on tackling the world’s toughest health challenges through 
on tackling the world's toughest health challenges through 
scientific innovation and technology.
scientific innovation and technology. 
We remain the world’s largest, most diversified healthcare 
We remain the world's largest, most diversified healthcare 
products company, and Johnson & Johnson is now moving 
products company, and Johnson & Johnson is now moving 
forward as a more focused and agile organization, with a 
forward as a more focused and agile organization, with a 
stronger growth and margin profile. 
stronger growth and margin profile. 
Operating as a company focused on delivering innovative 
Operating as a company focused on delivering innovative 
medicines and medical technologies has strengthened 
medicines and medical technologies has strengthened 
our position as an innovation powerhouse. Today, we are 
our position as an innovation powerhouse. Today, we are 
innovating for patients across a spectrum of healthcare 
innovating for patients across a spectrum of healthcare 
solutions in ways no other company can, and our impact  
solutions in ways no other company can, and our impact 
is significant.
is significant. 
Performance and priorities
Performance and priorities 
In 2023, we delivered strong and sustained performance 
In 2023, we delivered strong and sustained performance 
with 9.0% operational sales growth*, excluding the COVID-19 
with 9.0% operational sales growth*, excluding the COVID-19 
vaccine. Adjusted net earnings were $25.4 billion*. Adjusted 
vaccine. Adjusted net earnings were $25.4 billion*. Adjusted 
diluted net earnings per share was $9.92*, an increase of 
diluted net earnings per share was $9.92*, an increase of 
11.1% from 2022.
11.1% from 2022. 
We maintained a healthy balance sheet and robust credit 
We maintained a healthy balance sheet and robust credit 
rating, underscoring the stability of our financial position, 
rating, underscoring the stability of our financial position, 
and executed against all our capital allocation priorities. We 
and executed against all our capital allocation priorities. We 
remain a top investor in innovation, funding $15.1 billion in 
remain a top investor in innovation, funding $15.1 billion in 
R&D, or almost 18% of 2023 sales – an all-time high for the 
R&D, or almost 18% of 2023 sales —  an all-time high for the 
company.
company. 
We committed over $3 billion to external growth 
We committed over $3 billion to external growth 
opportunities in the last 12 months, including the acquisitions 
opportunities in the last 12 months, including the acquisitions 
of Ambrx and Laminar, and more than 50 smaller, early-stage 
of Ambrx and Laminar, and more than 50 smaller, early-stage 
licensing deals and partnerships. We increased our dividend 
licensing deals and partnerships. We increased our dividend 
for the 61st consecutive year and completed the share 
for the 61st consecutive year and completed the share 
repurchase program initiated in 2022, returning a total of 
repurchase program initiated in 2022, returning a total of 
over $14 billion to shareholders.
over $14 billion to shareholders. 
Innovative Medicine
Innovative Medicine 
We are leading where medicine is going, and for the 12th 
We are leading where medicine is going, and for the 12th 
consecutive year we reported above-market growth for 
consecutive year we reported above-market growth for 
our Innovative Medicine business. This strong performance 
our Innovative Medicine business. This strong performance 
was fueled by growth in key brands such as DARZALEX, 
was fueled by growth in key brands such as DARZALEX, 
ERLEADA, STELARA and TREMFYA, and the acceleration of 
ERLEADA, STELARA and TREMFYA, and the acceleration of 
recently launched products, including CARVYKTI, SPRAVATO, 
recently launched products, including CARVYKTI, SPRAVATO, 
TALVEY and TECVAYLI. 
TALVEY and TECVAYLI. 
We made significant advances in our pipeline, with FDA 
We made significant advances in our pipeline, with FDA 
approvals for AKEEGA and TALVEY, and positive Phase 
approvals for AKEEGA and TALVEY, and positive Phase 
III data readouts for 11 in-line and pipeline medicines. We 
III data readouts for 11 in-line and pipeline medicines. We 
initiated Phase III clinical development programs for milvexian 
initiated Phase III clinical development programs for milvexian 
and our targeted oral peptide, JNJ-2113, and received FDA 
and our targeted oral peptide, JNJ-2113, and received FDA 
Breakthrough Therapy Designation for TAR-200 for the 
Breakthrough Therapy Designation for TAR-200 for the 
treatment of bladder cancer. Milvexian also received FDA 
treatment of bladder cancer. Milvexian also received FDA 
Fast Track designations in atrial fibrillation, stroke, and acute 
Fast Track designations in atrial fibrillation, stroke, and acute 
coronary syndrome.
coronary syndrome. 
With 19 U.S. and EU filings across Innovative Medicine in 
With 19 U.S. and EU filings across Innovative Medicine in 
2023, we have high expectations for the year ahead.
2023, we have high expectations for the year ahead. 
MedTech
MedTech 
Innovating at the intersection of biology and technology, our 
Innovating at the intersection of biology and technology, our 
MedTech businesses delivered over $30 billion in sales, with 
MedTech businesses delivered over $30 billion in sales, with 
sales growth across Orthopaedics, Surgery, Interventional 
sales growth across Orthopaedics, Surgery, Interventional 
Solutions, and Vision. 
Solutions, and Vision. 
We progressed 20+ MedTech pipeline programs that each 
We progressed 20+ MedTech pipeline programs that each 
have an expected net present value of greater than $100 
have an expected net present value of greater than $100 
million, and launched 15 major products. To increase access 
million, and launched 15 major products. To increase access 
for patients and deliver clinical differentiation, we produced 
for patients and deliver clinical differentiation, we produced 
more than 200 scientific publications.
more than 200 scientific publications. 
We built on our commitment to interventional cardiology 
We built on our commitment to interventional cardiology 
with our successful integration of Abiomed and our 
with our successful integration of Abiomed and our 
acquisition of Laminar, a company focused on eliminating the 
acquisition of Laminar, a  company focused on eliminating the 
left atrial appendage to prevent stroke in AFib patients.
left atrial appendage to prevent stroke in AFib patients. 
2023 Annual Report
2023 Annual Report 
1
1 
 

--- Page 4 ---
Profoundly impacting health 
Profoundly impacting health 
for humanity
for humanity 
Science and technology will advance human health more in 
Science and technology will advance human health more in 
the next decade than in the last century. It will lead to more 
the next decade than in the last century. It will lead to more 
effective and personalized treatments, earlier intervention, 
effective and personalized treatments, earlier intervention, 
and smarter, less invasive healthcare. One example is in lung 
and smarter, less invasive healthcare. One example is in lung 
cancer, where doctors can use our robotic bronchoscopy 
cancer, where doctors can use our robotic bronchoscopy 
to make a diagnosis, perform surgery with our smart 
to make a  diagnosis, perform surgery with our smart 
instruments, and treat with our bispecific antibody. In so 
instruments, and treat with our bispecific antibody. In so 
many ways, we are just getting started. 
many ways, we are just getting started. 
We are energized by our future and our evolution at Johnson 
We are energized by our future and our evolution at Johnson 
& Johnson, and we remain grounded in our purpose and 
& Johnson, and we remain grounded in our purpose and 
guiding principles. For more than 80 years, Our Credo has 
guiding principles. For more than 80 years, Our Credo has 
reminded us of our responsibilities to the people we serve: 
reminded us of our responsibilities to the people we serve: 
patients, doctors and nurses, employees, communities, 
patients, doctors and nurses, employees, communities, 
and investors.
and investors. 
Our Credo values are as strong as ever. I see them in 
Our Credo values are as strong as ever. I see them in 
action every day working with my colleagues—a team of 
action every day working with my colleagues—a team of 
over 130,000 incredible individuals that includes more 
over 130,000 incredible individuals that includes more 
than 26,000 employees working in R&D, innovation, and 
than 26,000 employees working in R&D, innovation, and 
engineering, and approximately 6,000 data scientists and 
engineering, and approximately 6,000 data scientists and 
digital experts embedded across our businesses globally. 
digital experts embedded across our businesses globally. 
The people of Johnson & Johnson are my greatest source 
The people of Johnson & Johnson are my greatest source 
of inspiration and the foundation of my confidence in the 
of inspiration and the foundation of my confidence in the 
future of our business. Fueled by our shared belief that 
future of our business. Fueled by our shared belief that 
health is everything, and our commitment to investing 
health is everything, and our commitment to investing 
in transformative science and breakthrough technology, 
in transformative science and breakthrough technology, 
Johnson & Johnson is poised to lead the next wave of 
Johnson & Johnson is poised to lead the next wave of 
innovation. I look forward to seeing what we accomplish 
innovation. I look forward to seeing what we accomplish 
together in 2024 and beyond. 
together in 2024 and beyond. 
Sincerely, 
Sincerely, 
79A..citik 
Joaquin Duato
Joaquin Duato 
Duato 
Chairman and CEO
Chairman and CEO 
2
2 
Johnson&Johnson 
